PTBP1 Depletion in Mature Astrocytes Reveals Distinct Splicing Alterations Without Neuronal Features

  1. Division of Biomedical Sciences, University of California, Riverside, Riverside, United States
  2. Center for RNA Biology and Medicine, University of California, Riverside, United States
  3. Department of Molecular, Cell and Systems Biology, University of California, Riverside, United States

Peer review process

Not revised: This Reviewed Preprint includes the authors’ original preprint (without revision), an eLife assessment, public reviews, and a provisional response from the authors.

Read more about eLife’s peer review process.

Editors

  • Reviewing Editor
    Xin Duan
    University of California, San Francisco, San Francisco, United States of America
  • Senior Editor
    Sacha Nelson
    Brandeis University, Waltham, United States of America

Reviewer #1 (Public review):

Summary:

Zhang et al. used a conditional knockout mouse model to re-examine the role of the RNA-binding protein PTBP1 in the transdifferentiation of astroglial cells into neurons. Several earlier studies reported that PTBP1 knockdown can efficiently induce the transdifferentiation of rodent glial cells into neurons, suggesting potential therapeutic applications for neurodegenerative diseases. However, these findings have been contested by subsequent studies, which in turn have been challenged by more recent publications. In their current work, Zhang et al. deleted exon 2 of the Ptbp1 gene using an astrocyte-specific, tamoxifen-inducible Cre line and investigated, using fluorescence imaging and bulk and single-cell RNA-sequencing, whether this manipulation promotes the transdifferentiation of astrocytes into neurons across various brain regions. The data strongly indicate that genetic ablation of PTBP1 is not sufficient to drive efficient conversion of astrocytes into neurons. Interestingly, while PTBP1 loss alters splicing patterns in numerous genes, these changes do not shift the astroglial transcriptome toward a neuronal profile.

Strengths:

Although this is not the first report of PTBP1 ablation in mouse astrocytes in vivo, this study utilizes a distinct knockout strategy and provides novel insights into PTBP1-regulated splicing events in astrocytes. The manuscript is well written, and the experiments are technically sound and properly controlled. I believe this study will be of considerable interest to a broad readership.

Weaknesses:

(1) The primary point that needs to be addressed is a better understanding of the effect of exon 2 deletion on PTBP1 expression. Figure 4D shows successful deletion of exon 2 in knockout astrocytes. However, assuming that the coverage plots are CPM-normalized, the overall PTBP1 mRNA expression level appears unchanged. Figure 6A further supports this observation. This is surprising, as one would expect that the loss of exon 2 would shift the open reading frame and trigger nonsense-mediated decay of the PTBP1 transcript. Given this uncertainty, the authors should confirm the successful elimination of PTBP1 protein in cKO astrocytes using an orthogonal approach, such as Western blotting, in addition to immunofluorescence. They should also discuss possible reasons why PTBP1 mRNA abundance is not detectably affected by the frameshift.

(2) The authors should analyze PTBP1 expression in WT and cKO substantia nigra samples shown in Figure 3 or justify why this analysis is not necessary.

(3) Lines 236-238 and Figure 4E: The authors report an enrichment of CU-rich sequences near PTBP1-regulated exons. To better compare this with previous studies on position-specific splicing regulation by PTBP1, it would be helpful to assess whether the position of such motifs differs between PTBP1-activated and PTBP1-repressed exons.

(4) The analyses in Figure 5 and its supplement strongly suggest that the splicing changes in PTBP1-depleted astrocytes are distinct from those occurring during neuronal differentiation. However, the authors should ensure that these comparisons are not confounded by transcriptome-wide differences in gene expression levels between astrocytes and developing neurons. One way to address this concern would be to compare the new PTBP1 cKO data with publicly available RNA-seq datasets of astrocytes induced to transdifferentiate into neurons using proneural transcription factors (e.g., PMID: 38956165).

Reviewer #2 (Public review):

Summary:

The manuscript by Zhang and colleagues describes a study that investigated whether the deletion of PTBP1 in adult astrocytes in mice led to an astrocyte-to-neuron conversion. The study revisited the hypothesis that reduced PTBP1 expression reprogrammed astrocytes to neurons. More than 10 studies have been published on this subject, with contradicting results. Half of the studies supported the hypothesis while the other half did not. The question being addressed is an important one because if the hypothesis is correct, it can lead to exciting therapeutic applications for treating neurodegenerative diseases such as Parkinson's disease.

In this study, Zhang and colleagues conducted a conditional mouse knockout study to address the question. They used the Cre-LoxP system to specifically delete PTBP1 in adult astrocytes. Through a series of carefully controlled experiments, including cell lineage tracing, the authors found no evidence for the astrocyte-to-neuron conversion.

The authors then carried out a key experiment that none of the previous studies on the subject did: investigating alternative splicing pattern changes in PTBP1-depleted cells using RNA-seq analysis. The idea is to compare the splicing pattern change caused by PTBP1 deletion in astrocytes to what occurs during neurodevelopment. This is an important experiment that will help illuminate whether the astrocyte-to-neuron transition occurred in the system. The result was consistent with that of the cell staining experiments: no significant transition was detected.

These experiments demonstrate that, in this experimental setting, PTBT1 deletion in adult astrocytes did not convert the cells to neurons.

Strengths:

This is a well-designed, elegantly conducted, and clearly described study that addresses an important question. The conclusions provide important information to the field.
To this reviewer, this study provided convincing and solid experimental evidence to support the authors' conclusions.

Weaknesses:

The Discussion in this manuscript is short and can be expanded. Can the authors speculate what led to the contradictory results in the published studies? The current study, in combination with the study published in Cell in 2021 by Wang and colleagues, suggests that observed difference is not caused by the difference of knockdown vs. knockout. Is it possible that other glial cell types are responsible for the transition? If so, what cells? Oligodendrocytes?

Author response:

Public Reviews:

Reviewer #1 (Public review):

Summary:

Zhang et al. used a conditional knockout mouse model to re-examine the role of the RNA-binding protein PTBP1 in the transdifferentiation of astroglial cells into neurons. Several earlier studies reported that PTBP1 knockdown can efficiently induce the transdifferentiation of rodent glial cells into neurons, suggesting potential therapeutic applications for neurodegenerative diseases. However, these findings have been contested by subsequent studies, which in turn have been challenged by more recent publications. In their current work, Zhang et al. deleted exon 2 of the Ptbp1 gene using an astrocyte-specific, tamoxifen-inducible Cre line and investigated, using fluorescence imaging and bulk and single-cell RNA-sequencing, whether this manipulation promotes the transdifferentiation of astrocytes into neurons across various brain regions. The data strongly indicate that genetic ablation of PTBP1 is not sufficient to drive efficient conversion of astrocytes into neurons. Interestingly, while PTBP1 loss alters splicing patterns in numerous genes, these changes do not shift the astroglial transcriptome toward a neuronal profile.

Strengths:

Although this is not the first report of PTBP1 ablation in mouse astrocytes in vivo, this study utilizes a distinct knockout strategy and provides novel insights into PTBP1-regulated splicing events in astrocytes. The manuscript is well written, and the experiments are technically sound and properly controlled. I believe this study will be of considerable interest to a broad readership.

Weaknesses:

(1) The primary point that needs to be addressed is a better understanding of the effect of exon 2 deletion on PTBP1 expression. Figure 4D shows successful deletion of exon 2 in knockout astrocytes. However, assuming that the coverage plots are CPM-normalized, the overall PTBP1 mRNA expression level appears unchanged. Figure 6A further supports this observation. This is surprising, as one would expect that the loss of exon 2 would shift the open reading frame and trigger nonsense-mediated decay of the PTBP1 transcript. Given this uncertainty, the authors should confirm the successful elimination of PTBP1 protein in cKO astrocytes using an orthogonal approach, such as Western blotting, in addition to immunofluorescence. They should also discuss possible reasons why PTBP1 mRNA abundance is not detectably affected by the frameshift.

We thank the reviewer for raising this important point. Indeed, the deletion of exon 2 introduces a frameshift that is predicted to disrupt the PTBP1 open reading frame and trigger nonsensemediated decay (NMD). While our CPM-normalized coverage plots (Figure 4D) and gene-level expression analysis (Figure 6A) suggest that PTBP1 mRNA levels remain largely unchanged in cKO astrocytes, we acknowledge that this observation is counterintuitive and merits further clarification.

We suspect that the process of brain tissue dissociation and FACS sorting for bulk or single cell RNA-seq may enrich for nucleic material and thus dilute the NMD signal, which occurs in the cytoplasm. Alternatively, the transcripts (like other genes) may escape NMD for unknown mechanisms. Although a frameshift is a strong indicator for triggering NMD, it does not guarantee NMD will occur in every case. We will include this discussion in the revised manuscript to provide additional context for the apparent discrepancy between mRNA abundance and protein loss.

Regarding the validation of PTBP1 protein depletion in cKO astrocytes by Western blotting, we acknowledge that orthogonal approaches to confirm PTBP1 elimination would address uncertainty around the effect of exon 2 deletion on PTBP1 expression. The low cell yield of cKO astrocytes poses a significant burden on obtaining sufficient samples for immunoblotting detection of PTBP1 depletion. On average 3-5 adult animals per genotype are needed for each biological replicate. Our characterization of this Ptbp1 deletion allele in other contexts show the loss of full length PTBP1 proteins in ESCs and NPCs using Western blotting. Furthermore, germline homozygous mutant mice do not survive beyond embryonic day 6, supporting that it is a loss of function allele.

(2) The authors should analyze PTBP1 expression in WT and cKO substantia nigra samples shown in Figure 3 or justify why this analysis is not necessary.

We thank the reviewer for pointing out this important question. We used Aldh1l1-CreERT2, which is designed to be active in all the astrocyte throughout mouse brain. Although we have systematically verified PTBP1 elimination in different mouse brain regions (cortex and striatum) at multiple time points (from 4w to 12w after tamoxifen administration), we agree that it remains necessary and important to demonstrate whether the observed lack of astrocyte-to-neuron conversion is indeed associated with sufficient PTBP1 depletion. We will analyze the PTBP1 expression in the substantia nigra, as we did in the cortex and striatum.

(3) Lines 236-238 and Figure 4E: The authors report an enrichment of CU-rich sequences near PTBP1-regulated exons. To better compare this with previous studies on position-specific splicing regulation by PTBP1, it would be helpful to assess whether the position of such motifs differs between PTBP1-activated and PTBP1-repressed exons.

We thank the reviewer for this insightful comment. We agree that assessing the positional distribution of CU-rich motifs between PTBP1-activated and PTBP1-repressed exons would provide valuable insight into the position-specific regulatory mechanisms of PTBP1. In response, we will perform separate motif enrichment analyses for PTBP1-activated and PTBP1-repressed exons and examine whether their positional patterns differ. This will help clarify whether these exons are differentially regulated by PTBP1 through distinct motif positioning in mature astrocytes.

(4) The analyses in Figure 5 and its supplement strongly suggest that the splicing changes in PTBP1-depleted astrocytes are distinct from those occurring during neuronal differentiation. However, the authors should ensure that these comparisons are not confounded by transcriptome-wide differences in gene expression levels between astrocytes and developing neurons. One way to address this concern would be to compare the new PTBP1 cKO data with publicly available RNA-seq datasets of astrocytes induced to transdifferentiate into neurons using proneural transcription factors (e.g., PMID: 38956165).

We would like to express our gratitude for the thoughtful feedback. We agree that transcriptomewide differences in gene expression between astrocytes and developing neurons could confound the interpretation of splicing differences. To address this concern, we will incorporate publicly available RNA-seq datasets from studies in which astrocytes are reprogrammed into neurons using proneural transcription factors (PMID: 38956165).

Reviewer #2 (Public review):

Summary:

The manuscript by Zhang and colleagues describes a study that investigated whether the deletion of PTBP1 in adult astrocytes in mice led to an astrocyte-to-neuron conversion. The study revisited the hypothesis that reduced PTBP1 expression reprogrammed astrocytes to neurons. More than 10 studies have been published on this subject, with contradicting results. Half of the studies supported the hypothesis while the other half did not. The question being addressed is an important one because if the hypothesis is correct, it can lead to exciting therapeutic applications for treating neurodegenerative diseases such as Parkinson's disease.

In this study, Zhang and colleagues conducted a conditional mouse knockout study to address the question. They used the Cre-LoxP system to specifically delete PTBP1 in adult astrocytes. Through a series of carefully controlled experiments, including cell lineage tracing, the authors found no evidence for the astrocyte-to-neuron conversion.

The authors then carried out a key experiment that none of the previous studies on the subject did: investigating alternative splicing pattern changes in PTBP1-depleted cells using RNA-seq analysis. The idea is to compare the splicing pattern change caused by PTBP1 deletion in astrocytes to what occurs during neurodevelopment. This is an important experiment that will help illuminate whether the astrocyte-to-neuron transition occurred in the system. The result was consistent with that of the cell staining experiments: no significant transition was detected.

These experiments demonstrate that, in this experimental setting, PTBT1 deletion in adult astrocytes did not convert the cells to neurons.

Strengths:

This is a well-designed, elegantly conducted, and clearly described study that addresses an important question. The conclusions provide important information to the field.

To this reviewer, this study provided convincing and solid experimental evidence to support the authors' conclusions.

Weaknesses:

The Discussion in this manuscript is short and can be expanded. Can the authors speculate what led to the contradictory results in the published studies? The current study, in combination with the study published in Cell in 2021 by Wang and colleagues, suggests that observed difference is not caused by the difference of knockdown vs. knockout. Is it possible that other glial cell types are responsible for the transition? If so, what cells? Oligodendrocytes?

We are grateful for the reviewer’s careful reading and valuable suggestions. These will help us improve the manuscript. We will expand the Discussion. The contradictory results in the previously published studies can be due to the stringency and neuronal leakage of the astrocytespecific GFAP promoter that some investigators chose. Other possibilities include alternative cell origin, increased neuronal resilience, or combinations of as yet unidentified factors.

  1. Howard Hughes Medical Institute
  2. Wellcome Trust
  3. Max-Planck-Gesellschaft
  4. Knut and Alice Wallenberg Foundation